Skip to content
AnalystLens

BeOne Medicines Ltd. 8-K Report, Financial Results (Apr 28, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed April 28, 2025
Period End
April 28, 2025
Securities
ONCBEIGF
In the record · 2016–202610-K1310-Q328-K284

ONC filed 13 annual reports (10-K), 32 quarterly reports (10-Q) and 284 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Jun ’22Jun ’22
  4. Leadership change8-K · Jun ’26Jun ’26

01—Abstract

Summary

Summary of the 8-K filed April 28, 2025. Cited figures are marked; the original filing is the authoritative source.

This Form 8-K furnishes supplemental financial information, not a full earnings release.

It was filed alongside BeiGene's 2024 Annual Report on the Shanghai Stock Exchange STAR Market, which PRC rules require to include certain PRC GAAP disclosures. Exhibit 99.1 provides selected U.S. GAAP figures for 2024 and 2023: gross margin by region, R&D expenses by product, and production, sales, and inventory volumes. The filing names the registrant BeiGene, Ltd. rather than BeOne Medicines Ltd. The company renamed itself BeOne Medicines, so the name in the filing reflects the legacy entity name.

The Exhibit 99.1 disclosures are not part of the filed 8-K for Section 18 purposes, and the STAR report itself is Chinese-language only and not SEC-filed. The headline data point is revenue growth. Total revenue in the exhibit's gross margin table rose about 55% to $3.81 billiona in 2024 from $2.46 billion in 2023.

Ex-China revenue grew about 77% to $2.40 billionb, while China revenue grew about 28% to $1.41 billion. Ex-China growth therefore drove the mix shift, with ex-China now roughly 63% of revenue versus about 55% a year earlier. Implied total gross margin was essentially flat at roughly 84% on a simple revenue-less-COGS basis.

Regional margins compressed modestly: China fell to 62.9% from 68.0%, reflecting pricing and volume-based procurement pressure, while ex-China slipped to 97.1% from 98.0%. R&D spending rose about 10% to $1.95 billionc. The increase was concentrated in pipeline assets.

BCL-2 inhibitor BGB-11417 (sonrotoclax) spending nearly doubled to $99.9 milliond, and early-stage programs CDAC (BGB-16673) and CDK4 (BGB-43395) rose sharply from small bases. External R&D collaboration spending nearly doubled to $189.2 million. Zanubrutinib R&D expense declined to $129.2 million from $158.1 million.

On the commercial side, the company sold about 5.04 million vials of key products against about 5.01 million produced or purchased in 2024, leaving about 2.64 million vials in inventory at year-end. This filing does not provide forward guidance, so the implications for future periods must be drawn from the underlying annual report.

02—Key points

Key Highlights

  1. Total 2024 revenue of about $3.81 billion (U.S. GAAP basis) rose roughly 55% from $2.46 billion in 2023, the strongest growth in the disclosed data.
  2. Ex-China revenue grew about 77% to $2.40 billion, while China revenue grew about 28% to $1.41 billion, shifting the revenue mix toward markets outside China (about 63% of 2024 revenue).
  3. Regional gross margins compressed: China fell to 62.9% from 68.0%, and ex-China eased to 97.1% from 98.0%. Implied total gross margin was roughly flat at about 84%.
  4. Total R&D expense rose about 10% to $1.95 billion, with internal R&D at $1.22 billion and external R&D at $729 million.
  5. The BCL-2 program (BGB-11417) R&D spend nearly doubled to $99.9 million, and CDAC and CDK4 programs increased sharply, signaling investment in newer pipeline assets.
  6. Zanubrutinib R&D spending declined to $129.2 million from $158.1 million, consistent with a more mature product in the portfolio.
  7. Inventory was about 2.64 million vials at December 31, 2024, after sales of about 5.04 million vials against about 5.01 million produced or purchased.

03—Questions

Frequently Asked Questions

  1. Does this 8-K provide new full-year earnings or guidance?

    No. The filing furnishes supplemental information required by PRC securities rules: selected U.S. GAAP figures for gross margin, R&D by product, and production and sales volumes. It contains no full income statement, balance sheet, cash flow statement, or forward guidance. Investors should rely on the company's Form 10-K and earnings releases for complete results.

  2. Why does the filing show different accounting bases, and does it matter for investors?

    The STAR Annual Report uses PRC GAAP (CAS), which differs from U.S. GAAP. The main differences noted are share-based compensation (accelerated versus straight-line expense recognition, plus tax-benefit treatment) and lease accounting (separate interest and depreciation presentation under PRC GAAP, which front-loads expense). Investors comparing figures across reports should use the U.S. GAAP numbers in Exhibit 99.1, since the Chinese-language STAR report is not SEC-filed.

  3. What drove the decline in China gross margin?

    The filing does not explicitly attribute the decline. China gross margin fell to 62.9% from 68.0% while China COGS rose to $524 million from $353 million, faster than China revenue growth of 28%. Pricing pressure and product or channel mix are plausible contributors, but the exhibit does not confirm the cause, so investors should check the annual report's management discussion.

  4. Is the company's R&D spending shifting toward new programs?

    Yes, based on the data provided. Total R&D rose about 10%, but the increase came from newer assets: BCL-2 (BGB-11417) spending nearly doubled, CDAC and CDK4 rose from small bases, and R&D collaboration spending nearly doubled to $189 million. Spending on zanubrutinib and tislelizumab declined, and 'other R&D projects' fell to $215 million from $252 million.

04—Continue

← View all 8-K filings